Climb Bio Stock Cash Flow From Operations
| CLYM Stock | 1.60 0.15 10.34% |
Fundamental analysis of Climb Bio allows traders to better anticipate movements in Climb Bio's stock price by examining its financial health and performance throughout various phases of its business cycle.
Climb | Cash Flow From Operations | Build AI portfolio with Climb Stock |
Climb Bio Company Cash Flow From Operations Analysis
Climb Bio's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Climb Bio Cash Flow From Operations | (15.56 M) |
Most of Climb Bio's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Climb Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Climb Cash Flow From Operations Driver Correlations
Understanding the fundamental principles of building solid financial models for Climb Bio is extremely important. It helps to project a fair market value of Climb Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since Climb Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Climb Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Climb Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Climb Bio has (15.56 Million) in Cash Flow From Operations. This is 102.95% lower than that of the Biotechnology sector and 124.89% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 101.6% higher than that of the company.
Climb Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Climb Bio's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Climb Bio could also be used in its relative valuation, which is a method of valuing Climb Bio by comparing valuation metrics of similar companies.Climb Bio is currently under evaluation in cash flow from operations category among its peers.
Climb Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of Climb Bio from analyzing Climb Bio's financial statements. These drivers represent accounts that assess Climb Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Climb Bio's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 91.3M | 96.0M | 206.0M | 211.3M | 86.7M | 99.3M | |
| Enterprise Value | 70.8M | 49.1M | 162.9M | 118.5M | (3.1K) | (2.9K) |
Climb Fundamentals
| Return On Equity | -0.62 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | (11.77 M) | ||||
| Shares Outstanding | 67.58 M | ||||
| Shares Owned By Insiders | 7.95 % | ||||
| Shares Owned By Institutions | 84.98 % | ||||
| Number Of Shares Shorted | 1.38 M | ||||
| Price To Book | 0.44 X | ||||
| EBITDA | (30.36 M) | ||||
| Net Income | (73.9 M) | ||||
| Total Debt | 532 K | ||||
| Book Value Per Share | 2.86 X | ||||
| Cash Flow From Operations | (15.56 M) | ||||
| Short Ratio | 14.68 X | ||||
| Earnings Per Share | (1.78) X | ||||
| Target Price | 10.0 | ||||
| Number Of Employees | 17 | ||||
| Beta | -0.11 | ||||
| Market Capitalization | 85.82 M | ||||
| Total Asset | 217.19 M | ||||
| Retained Earnings | (229.88 M) | ||||
| Working Capital | 149.94 M | ||||
| Net Asset | 217.19 M |
About Climb Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Climb Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Climb Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Climb Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Climb Bio Piotroski F Score and Climb Bio Altman Z Score analysis. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Climb Bio. If investors know Climb will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Climb Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Climb Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Climb Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Climb Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.